Research can establish that a screening approach is useful. Making it work across a population is another challenge.
Experience with lung-cancer screening brings that distinction into focus. Low-dose CT screening requires a whole pathway: identifying eligible people, explaining the choice, arranging the scan, interpreting findings, and completing any necessary follow-up.
Access begins before the appointment
A person may be eligible for screening without knowing it. Invitations, primary-care conversations, and community outreach help people find their way into a program. Cost, travel, time away from work, and language can all affect whether that invitation leads to an appointment.
Eligibility is also specific to a program. The US Preventive Services Task Force recommendation uses age and smoking history, alongside considerations about health and the ability to undergo treatment. Other countries have developed programs around their own populations and health systems. A single set of criteria cannot simply be assumed to apply everywhere.
A positive result starts a process
Screening can find abnormalities that need further investigation. Some will be cancer; others will not. Programs need a clear way to explain the result and arrange the next step.
Follow-up is therefore part of the design, rather than an afterthought. It affects the experience of participants, the demands on services, and whether an early signal leads to timely care.
Different systems offer different lessons
South Korea’s national program and Taiwan’s early-detection program show why implementation must consider local risk, infrastructure, and access. The important comparison is broader than how many scans are performed. It includes who participates, who is missed, and what happens after a finding.
For researchers, these questions influence study design too. A cohort should reflect the intended setting, and the outcomes should help explain how an approach might fit into an actual pathway.
What this means for new detection approaches
New biomarker-based approaches will enter a world with existing screening and diagnostic pathways. They need to be studied in that context: who might benefit, what the measurement adds, and what a result would lead to.
At BioMarkIQ, lung cancer is our first disease focus. The lesson we take from screening programs is practical: build the science around a clearly defined question, while keeping the eventual pathway in view.
Sources and further reading
- USPSTF: Lung cancer screening recommendation
- Lung Cancer Policy Network: Implementing a national screening programme in South Korea
- IASLC: Taiwan launches national lung cancer early detection program
From the BioMarkIQ archive. Edited and updated on 17 October 2026.